How to buy Replimune Group stock

Replimune Group, Inc is a biotechnology business based in the US. Replimune Group shares (REPL) are listed on the NASDAQ and all prices are listed in US Dollars. Replimune Group employs 122 staff and has a market cap (total outstanding shares value) of USD$1.7 billion.

How to buy shares in Replimune Group

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Replimune Group. Find the stock by name or ticker symbol: REPL. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Replimune Group reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Replimune Group, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Replimune Group. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced traders

Interactive Brokers

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active traders. We picked Interactive Brokers for this category because it offers advanced tools and low fees for active investors and pros. The simpler IBKR Lite platform is aimed at less-active investors, but all users older than 21 must meet a $20,000 liquid net worth requirement for a cash account.

What's in this guide?

1. REPL shares summary
2. Compare share dealing platforms
3. Is REPL stock a buy or sell?
4. Stock performance over time
5. Can I short REPL shares?
6. Replimune Group's financials
7. How volatile are REPL shares?
8. Does Replimune Group pay a dividend?
9. Other common questions

Replimune Group share price

Use our graph to track the performance of REPL stocks over time.

Replimune Group shares at a glance

• Key figures

Information last updated 2021-02-24.

52-week range	USD$8.58 - USD$54.85
50-day moving average	USD$40.6088
200-day moving average	USD$36.4733
Wall St. target price	USD$56.3
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.014

Buy Replimune Group shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Moomoo		$0 for US stocks	Stocks, Options, ETFs	$0		N/A	Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Replimune Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Replimune Group, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Replimune Group shares

There are currently 2.5 million Replimune Group shares held short by investors – that's known as Replimune Group's "short interest". This figure is 16.8% down from 3.0 million last month.

There are a few different ways that this level of interest in shorting Replimune Group shares can be evaluated.

Replimune Group's "short interest ratio" (SIR)

Replimune Group's "short interest ratio" (SIR) is the quantity of Replimune Group shares currently shorted divided by the average quantity of Replimune Group shares traded daily (recently around 441554.94699647). Replimune Group's SIR currently stands at 5.66. In other words for every 100,000 Replimune Group shares traded daily on the market, roughly 5660 shares are currently held short.

However Replimune Group's short interest can also be evaluated against the total number of Replimune Group shares, or, against the total number of tradable Replimune Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Replimune Group's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Replimune Group shares in existence, roughly 50 shares are currently held short) or 0.1127% of the tradable shares (for every 100,000 tradable Replimune Group shares, roughly 113 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Replimune Group.

Find out more about how you can short Replimune Group stock.

Replimune Group share price volatility

Over the last 12 months, Replimune Group's shares have ranged in value from as little as $8.58 up to $54.85. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Replimune Group's is 2.6296. This would suggest that Replimune Group's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Replimune Group overview

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Frequently asked questions

• What percentage of Replimune Group is owned by insiders or institutions?

  Currently 9.413% of Replimune Group shares are held by insiders and 77.934% by institutions.

• How many people work for Replimune Group?

  Latest data suggests 122 work at Replimune Group.

• When does the fiscal year end for Replimune Group?

  Replimune Group's fiscal year ends in March.

• Where is Replimune Group based?

  Replimune Group's address is: 500 Unicorn Park, Woburn, MA, United States, 01801

• What is Replimune Group's ISIN number?

  Replimune Group's international securities identification number is: US76029N1063

• What is Replimune Group's CUSIP number?

  Replimune Group's Committee on Uniform Securities Identification Procedures number is: 76029N106